Category: Dravet syndrome

1, analysis, analytics, and Cosmetics Act, application, approval, approve, business, Business Analysis, cannabidiol, cannabis, cbd, clinical, clinical trials, compliance, consumer packaged goods, CPG, CSA, dea, derived, deschedule, descheduled, Dravet syndrome, drug, Drug Enforcement Administration, Epidiolex, epilepsy, extraction, FDA, FDCA, Federal, Federal Food, FFDCA, food and drug administration, formulation, government, GW, GW Pharma, hemp, industry, law, legal, legalization, legalize, legislation, Lennox-Gastaut syndrome, license, marijuana, market, medical, medicine, New, patent, pathway, patient, pharma, pharmaceutical, product, Product Development, program, regulation, regulations, regulatory, REMS, safety, schedule, seizures, state, Substances, thc, trial, TSC

How GW Pharma Won CBD

How GW Pharma Won CBD

As of this writing, the United States Food and Drug Administration (FDA) has approved GW Pharma’s CBD drug Epidiolex for treating profound […]

cannabidiol, Cannabis Industry & Marijuana Business Briefs, cbd, Dravet syndrome, Epidiolex, Europe Cannabis Industry & Marijuana Business News, FDA, GW Pharmaceuticals, International Marijuana Business News, Lennox-Gastaut syndrome, Medical Cannabis Industry & Recreational Marijuana Business News, tuberous sclerosis complex, U.S. Food and Drug Administration, United States Cannabis Industry & Marijuana Business News

FDA approves GW Pharmaceuticals’ cannabis drug for new indication

CBD drug Epidiolex received approval from the U.S. Food and Drug Administration to treat seizures associated with a third medical condition, expanding […]